Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., recently sold 513 shares of common stock as part of a transaction to satisfy tax withholding requirements. This sale, executed on October 22, 2026, is significant as it reflects the financial activities of a key executive within the company.
The sale was reported in a filing made on October 26, 2026, and is part of Miller's ongoing management of her stock holdings. Such transactions are common among executives, especially when they involve shares acquired through restricted stock units.
Background
Acrivon Therapeutics, Inc. operates in the pharmaceutical preparations sector, with a focus on developing innovative therapies. The company is based in Watertown, Massachusetts, and is publicly traded under the ticker symbol ACRV. Recent filings indicate that Acrivon is actively engaged in various corporate activities, as reflected in its multiple Form 4 filings.
What the Filing Says
The filing states, "Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units." The transaction was executed at a price of $1.84 per share, reflecting the weighted average price for the shares sold.
Impact
This transaction may affect Acrivon’s stakeholders, including investors and analysts who monitor executive actions as indicators of company health and management confidence. The pharmaceutical preparations industry, where Acrivon operates, often scrutinizes such transactions to gauge executive sentiment regarding company performance.
What's Next
The filing does not say what happens next.